Therefore, it is crucial to engage in rigorous scientific investigations to establish the generalizability of YAP/TAZ-mediated resistance to KRAS inhibition across a wide spectrum of tumor types and distinct KRAS mutation variants. The gene discussed is KRAS; the disease is neoplasm.